Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Spero Therapeutics appoints new CMO
Business executive appointment

Spero Therapeutics appoints new CMO

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
10
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment is a positive signal for Spero's clinical development capabilities, potentially boosting investor confidence. Spero's stock rose nearly 2% in pre-market trading following the announcement.

biotechnology pharmaceuticals
Event Summary

Spero Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. Dr. Zack brings over 25 years of experience in developing therapies for immune-mediated diseases, having previously served as CMO of Exagen Inc. and held leadership roles at Xencor Inc. and Novartis. She will lead Spero's clinical development strategy as the company advances SP001, a Phase 2-ready anti-CD40L antibody for IgG4-related disease and other immune conditions. The appointment is effective immediately.

Key Actions
50 Spero Therapeutics appointed Debra Jeske Zack
Entities Involved
stock
Spero Therapeutics
Spero Therapeutics appointed a new CMO to lead clinical development of its lead asset SP001, signaling progress in its pipeline.
Importance 100.0 Sentiment 10.0
per
Debra Jeske Zack
Debra Jeske Zack was appointed as Chief Medical Officer, bringing extensive experience in immunology and drug development.
Importance 100.0 Sentiment 10.0
per
Esther Rajavelu
Esther Rajavelu, as CEO, welcomed the new CMO and highlighted her expertise for advancing Spero's clinical strategy.
Importance 50.0 Sentiment 5.0
stock
Amgen
Amgen is mentioned as a previous employer of Dr. Zack, where she served as Global Development Lead for Enbrel.
Importance 10.0 Sentiment 0.0
stock
Exagen Inc.
Exagen Inc. is mentioned as Dr. Zack's most recent employer before joining Spero.
Importance 10.0 Sentiment 0.0
stock
Xencor Inc.
Xencor Inc. is mentioned as a previous employer where Dr. Zack held clinical leadership roles.
Importance 10.0 Sentiment 0.0
stock
Novartis
Novartis is mentioned as a previous employer where Dr. Zack worked in the Biotherapeutics Development Unit.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Spero Therapeutics is listed under ticker SPRO.
Importance 5.0 Sentiment 0.0
Relationships
Amgen related ↔ Novartis
Amgen related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.